FDA Withdraws Ixchiq Chikungunya Vaccine Accelerated Approval, Updating Infectious Disease AA Registry

Ixchiq's withdrawal from FDA's accelerated approval registry on January 29, 2026, less than 27 months after its November 2023 grant, sharpens the postmarketing commitment calculus for regulatory teams managing live vaccine portfolios under the accelerated approval pathway. The chikungunya vaccine, developed for active immunization in adults 18 and older at increased exposure risk, failed to convert to full approval, and FDA has now published the withdrawal across two separate postmarketing requirement entries, each tied to distinct confirmatory study obligations.

The dual-entry structure in the registry is not a clerical artifact. FDA's notation confirms that the two Ixchiq lines reflect two discrete postmarketing requirements released upon withdrawal, consistent with 21 CFR Part 601 biologics withdrawal procedures and the agency's Federal Register notice obligations. Regulatory affairs leads should treat this as a procedural signal: when accelerated approvals carry multiple PMRs, each commitment tracks independently and each can generate a separate withdrawal record.

The broader registry context is instructive. Withdrawn infectious disease accelerated approvals now span more than two decades, from Cipro's 2004 anthrax post-exposure withdrawal through multiple Levaquin entries resolved between 2017 and 2021, to Sulfamylon's 2022 exit. The Ixchiq withdrawal is the most recent and the only vaccine on the list, distinguishing it from the small-molecule and antimicrobial precedents that dominate the historical record. For QA directors and regulatory leads at vaccine manufacturers, the compressed timeline between accelerated approval and withdrawal underscores that confirmatory trial design and enrollment velocity are not post-approval administrative tasks, they are approval-sustaining obligations.

FDA's guidance directs stakeholders to Drugs@FDA for current labeling and to the Postmarket Requirements and Commitments database for live PMR status. The Federal Register notice date governs the official withdrawal record, which may differ from the applicant's submission date or the FDA action date, a distinction relevant to any manufacturer reconciling internal compliance timelines against the public registry.

Regulatory teams with accelerated approvals in active infectious disease or biologics programs should audit current PMR milestones against enrollment projections before the next scheduled FDA meeting cycle, using the Ixchiq precedent as a benchmark for withdrawal velocity when confirmatory data do not materialize on schedule.

Source: FDA Drugs Accelerated Approval Program via What's New: Drugs RSS Feed, May 15, 2026. Additional biologics discontinuation detail available at FDA CBER Regulated Products Permanent Discontinuations page.